3 Things In Biotech You Should Learn Today: September 6, 2017 – Seeking Alpha
|
3 Things In Biotech You Should Learn Today: September 6, 2017
Seeking Alpha Cellectis (CLLS) is developing a novel target for CAR–T cells, CD123, with the ultimate goal of treating acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). CLLS has moved quickly in 2017, receiving approval to … |
